

# A Phase a Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis

NCT06474442

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Shanghai BDgene Co., Ltd.
Enrollment	40 participants

## Key Eligibility Criteria

---

### Inclusion (12)

- Aged 18 to 70 years old;
- Clinically diagnosed with herpes simplex virus stromal keratitis;
- Tear swab HSV-1 nucleic acid test (qPCR method) positive;
- No use of systemic antiviral drugs or corticosteroids within 48 hours before enrollment;
- No systemic immune eye diseases;

... and 7 more (see full listing online)

### Exclusion (23)

- Active ocular infection caused by other pathogens in the target eye or the fellow eye within 30 days before enrollment, including but not limited to blepharitis, infectious conjunctivitis, keratitis, scleritis, and endophthalmitis;
- Patients with bilateral viral keratitis
- Previous corneal transplant surgery in the study eye;
- A history of adverse reactions or allergies to corticosteroids and sodium fluorescein, allergies to therapeutic or diagnostic protein products, allergies to e two drugs or non-drug factors, or having an ongoing allergic disease;
- Absence of tear film and blinking function;

... and 18 more (see full listing online)

## Locations (1 total)

---

Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China